Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 20/20 | 0.89 |
| ▸ | MMP14 | P50281 | 11/20 | 0.82 |
| ▸ | MMP2 | P08253 | 11/20 | 0.69 |
| ▸ | MMP13 | P45452 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17871480 | 0.94 | ADAMTS5 (1.00) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL17884634 | 0.94 | ADAMTS5 (1.00) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL17884631 | 0.94 | ADAMTS5 (1.00) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL17884805 | 0.92 | ADAMTS5 (0.87) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL17871114 | 0.91 | ADAMTS5 (1.00) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL17871248 | 0.90 | ADAMTS5 (1.00) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL17884637 | 0.88 | ADAMTS5 (0.77) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL17871323 | 0.86 | ADAMTS5 (1.00) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL17884629 | 0.86 | ADAMTS5 (0.80) | ADAMTS5MMP14MMP2MMP13 | |
| SCHEMBL19759011 | 0.86 | ADAMTS5 (0.80) | ADAMTS5MMP14MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | ADAMTS5 2/4885MMP14 38/4885MMP2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.